Thymosin Alpha-1 and Warfarin Interaction: What Clinicians and Patients Need to Know

HealthRX.com

No warfarin interaction is listed for thymosin alpha-1

Print or save as PDF

  • Interaction listed in the warfarin label / none for thymosin alpha-1 [1]
  • Warfarin label rule / more frequent INR checks when starting or stopping other drugs [1]
  • Thymosin alpha-1 in the US / not FDA-approved; approved as a medicine in some other countries [2]
  • Ta1 half-life / about 1.8 to 2.6 hours, no accumulation over five daily doses [2]
  • Warfarin boxed warning / major or fatal bleeding [1]

Does thymosin alpha-1 interact with warfarin?

The Jantoven (warfarin sodium) label has one table of CYP2C9, CYP1A2 and CYP3A4 inhibitors and inducers, and another of drugs that add to bleeding risk, including other anticoagulants, antiplatelets, NSAIDs and SSRIs [1]. Thymosin alpha-1 appears in neither table. The Italian Zadaxin label's caution about co-medication refers to other immune-modulating drugs [2].

Not being named in the label is not evidence of safety, and the label gives no information on whether thymosin alpha-1 changes INR.

What the warfarin label asks for when another drug starts

The label says to monitor INR regularly in all treated patients and more often when starting or stopping other drugs, including botanicals, or changing their doses [1]. It names enzyme induction, enzyme inhibition and reduced plasma protein binding as the pharmacokinetic mechanisms. The more potent S-enantiomer is metabolized by CYP2C9 and R-warfarin by CYP1A2 and CYP3A4, so inhibitors can raise INR and inducers can lower it [1]. On initiation it advises daily INR checks until the patient is stable in range, then every 1 to 4 weeks [1].

What thymosin alpha-1 is and how it behaves

Thymosin alpha-1 is a 28-amino-acid peptide [2]. It is described as an immune modulator that augments T-cell function [3]. After subcutaneous injection it peaks at about 0.7 to 2 hours and clears with a half-life of about 1.8 to 2.6 hours [2][3]. No accumulation was observed after daily dosing for five days [2]. No US-approved dose exists. The Italian Zadaxin label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination. It calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [2].

Regulatory status

Thymosin alpha-1 is not FDA-approved; its four US orphan drug designations are a separate process from approval [2]. It is approved as a medicine in some other countries, including Italy, India and Hong Kong [2]. FDA lists it in the table of bulk substances that were in category 2 (significant safety risks) and were withdrawn by the nominators. FDA's posted concerns include immunogenicity for certain routes of administration, peptide impurities and characterization, and safety information the agency calls inadequate [4].

What to watch for on warfarin

Warfarin's boxed warning is bleeding: it can cause major or fatal bleeding, and drugs and dietary changes shift INR levels [1]. Bleeding is more likely in the first month, and keeping the INR in range does not remove the risk [1].

Questions worth asking

Choose the questions you want to keep

Does thymosin alpha-1 interact with warfarin?
Thymosin alpha-1 appears in neither of the warfarin label's interaction tables, and the label calls for more frequent INR checks whenever another drug is started or stopped [1].
Does thymosin alpha-1 affect INR?
The Jantoven label does not mention thymosin alpha-1 and gives no INR change for it [1]. Thymosin alpha-1 is described as an immune modulator that augments T-cell function [3].
Is thymosin alpha-1 FDA-approved?
No. Its four US orphan drug designations are not approvals. It is approved as a medicine in some other countries, including Italy, India and Hong Kong [2].
What does the warfarin label say when a new drug starts?
The Jantoven label says to monitor INR regularly and more often when starting or stopping other drugs, including botanicals; at initiation, daily INR checks until stable in range, then every 1 to 4 weeks [1].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Is it safe to take thymosin alpha 1?

It is not established as safe. Thymosin alpha-1 is not FDA-approved, and no US-approved dose exists. FDA's posted concerns include immunogenicity for certain routes of administration, peptide impurities and characterization, and safety information the agency calls inadequate. The Italian Zadaxin label calls for caution in people with allergies or autoimmune disease.

What are the potential drug interactions with warfarin?

The warfarin label has two interaction tables. One lists CYP2C9, CYP1A2 and CYP3A4 inhibitors and inducers. The other lists drugs that add to bleeding risk, including other anticoagulants, antiplatelets, NSAIDs and SSRIs. Inhibitors can raise INR and inducers can lower it, so the label calls for more frequent INR checks when other drugs, botanicals included, are started or stopped.

Show all 4 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Jantoven (warfarin sodium) tablets, Upsher-Smith prescribing information. Jantoven (warfarin sodium) tablets, Upsher-Smith label
  2. U.S. Food and Drug Administration.
  3. Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8.
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
Evidence overview for Thymosin Alpha-1 and Warfarin Interaction: What Clinicians and Patients Need to Know